Company intelligence / Profile preview
AMD Therapeutics
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
AMD Therapeutics was a biotechnology company focused on developing novel treatments for age-related macular degeneration (AMD). The company's primary asset was a topical formulation of squalamine, a small molecule anti-angiogenic compound intended to treat the wet form of AMD. In June 2008, the company was acquired by Ohr Pharmaceutical, which continued the development of squalamine eye drops through Phase 2 clinical trials. The acquisition aimed to leverage AMD Therapeutics' specialized focus on ophthalmology to expand Ohr's pipeline in the retinal disease space.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on AMD Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMD Therapeutics.